Drugs / IBI3031
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07622368 | Jun 2026 → Jun 2027 expected | endocrine exophthalmos | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07622368 ↗ |
| Route | Intravenous | “subcutaneous injection or intravenous infusion.” NCT07622368 ↗ |
| Route | Subcutaneous | “subcutaneous injection or intravenous infusion.” NCT07622368 ↗ |
| Target | TSHR | “IBI3031 is an IGF-1R(Insulin-like growth factor 1 receptor)/TSHR(Thyroid-stimulating hormone receptor) bispecific antibody” NCT07622368 ↗ |